Tumor-specific CTL responses are initiated at secondary lymphoid organs when naïve CD8+ T cells are activated by mature migratory dendritic cells (DCs) presenting tumor-derived antigens on MHC class I molecules1,2. Here, CD8A is linked to neoplasm.